Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations
Identifieur interne : 001C65 ( PascalFrancis/Curation ); précédent : 001C64; suivant : 001C66Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations
Auteurs : Albert F. G. Leentjens [Pays-Bas] ; Kathy Dujardin [France] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Irene H. Richard [États-Unis] ; Sergio E. Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Christina Sampaio [Portugal] ; Werner Poewe [Autriche] ; Oliver Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Recommandation.
English descriptors
- KwdEn :
Abstract
Anxiety syndromes are common in patients with Parkinson's disease (PD) with up to 30% suffering from panic disorder, and up to 11% from generalized anxiety disorder (GAD). Anxiety is associated with increased subjective motor symptoms, more severe gait problems, dyskinesias, freezing, and on/off fluctuations. Anxiety has a negative impact on health related quality of life and is strongly associated with depressive syndromes. Since a variety of anxiety scales have been used in PD patients, the Movement Disorder Society commissioned a task force to assess the clinimetric properties of these scales in PD. A systematic review was conducted to identify anxiety scales that have either been validated or used in patients with PD. Six anxiety rating scales were identified. These were the Beck anxiety inventory, the hospital anxiety and depression scale, the Zung self-rating anxiety scale and anxiety status inventory, the Spielberger state trait anxiety inventory, and the Hamilton anxiety rating scale. In addition, Item 5 (anxiety) of the neuropsychiatric inventory was included in the review. No scales met the criteria to be "recommended," and all scales were classified as "suggested." Essential clinimetric information is missing for all scales. Because several scales exist and have been used in PD, the task force recommends further studies of these instruments. If these studies show that the clinimetric properties of existing scales are inadequate, development of a new scale to assess anxiety in PD should be considered.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001054
Links to Exploration step
Pascal:08-0536689Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle, Western Australia</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sampaio, Christina" sort="Sampaio, Christina" uniqKey="Sampaio C" first="Christina" last="Sampaio">Christina Sampaio</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Lahoratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0536689</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0536689 INIST</idno>
<idno type="RBID">Pascal:08-0536689</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001054</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001C65</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle, Western Australia</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sampaio, Christina" sort="Sampaio, Christina" uniqKey="Sampaio C" first="Christina" last="Sampaio">Christina Sampaio</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Lahoratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term>
<term>Depression</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Psychometrics</term>
<term>Recommendation</term>
<term>Reliability</term>
<term>Validity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Angoisse anxiété</term>
<term>Maladie de Parkinson</term>
<term>Etat dépressif</term>
<term>Pathologie du système nerveux</term>
<term>Recommandation</term>
<term>Psychométrie</term>
<term>Validité</term>
<term>Fiabilité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Recommandation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Anxiety syndromes are common in patients with Parkinson's disease (PD) with up to 30% suffering from panic disorder, and up to 11% from generalized anxiety disorder (GAD). Anxiety is associated with increased subjective motor symptoms, more severe gait problems, dyskinesias, freezing, and on/off fluctuations. Anxiety has a negative impact on health related quality of life and is strongly associated with depressive syndromes. Since a variety of anxiety scales have been used in PD patients, the Movement Disorder Society commissioned a task force to assess the clinimetric properties of these scales in PD. A systematic review was conducted to identify anxiety scales that have either been validated or used in patients with PD. Six anxiety rating scales were identified. These were the Beck anxiety inventory, the hospital anxiety and depression scale, the Zung self-rating anxiety scale and anxiety status inventory, the Spielberger state trait anxiety inventory, and the Hamilton anxiety rating scale. In addition, Item 5 (anxiety) of the neuropsychiatric inventory was included in the review. No scales met the criteria to be "recommended," and all scales were classified as "suggested." Essential clinimetric information is missing for all scales. Because several scales exist and have been used in PD, the task force recommends further studies of these instruments. If these studies show that the clinimetric properties of existing scales are inadequate, development of a new scale to assess anxiety in PD should be considered.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>14</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LEENTJENS (Albert F. G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DUJARDIN (Kathy)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARSH (Laura)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RICHARD (Irene H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STARKSTEIN (Sergio E.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WEINTRAUB (Daniel)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SAMPAIO (Christina)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>RASCOL (Oliver)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>STEBBINS (Glenn T.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle, Western Australia</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Lahoratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>2015-2025</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000184512460090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>69 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0536689</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Anxiety syndromes are common in patients with Parkinson's disease (PD) with up to 30% suffering from panic disorder, and up to 11% from generalized anxiety disorder (GAD). Anxiety is associated with increased subjective motor symptoms, more severe gait problems, dyskinesias, freezing, and on/off fluctuations. Anxiety has a negative impact on health related quality of life and is strongly associated with depressive syndromes. Since a variety of anxiety scales have been used in PD patients, the Movement Disorder Society commissioned a task force to assess the clinimetric properties of these scales in PD. A systematic review was conducted to identify anxiety scales that have either been validated or used in patients with PD. Six anxiety rating scales were identified. These were the Beck anxiety inventory, the hospital anxiety and depression scale, the Zung self-rating anxiety scale and anxiety status inventory, the Spielberger state trait anxiety inventory, and the Hamilton anxiety rating scale. In addition, Item 5 (anxiety) of the neuropsychiatric inventory was included in the review. No scales met the criteria to be "recommended," and all scales were classified as "suggested." Essential clinimetric information is missing for all scales. Because several scales exist and have been used in PD, the task force recommends further studies of these instruments. If these studies show that the clinimetric properties of existing scales are inadequate, development of a new scale to assess anxiety in PD should be considered.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Angoisse anxiété</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Anxiety</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Angustia ansiedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Depression</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Recommandation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Recommendation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Recomendación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Psychométrie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Psychometrics</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Psicometría</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Validité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Validity</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Validez</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Fiabilité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Reliability</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Fiabilidad</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Affect affectivité</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Affect affectivity</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Afecto afectividad</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>43</s5>
</fC07>
<fN21><s1>350</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001C65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:08-0536689 |texte= Anxiety Rating Scales in Parkinson's Disease : Critique and Recommendations }}
This area was generated with Dilib version V0.6.23. |